Achieve Life Sciences, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
Achieve Life Sciences, Inc. (ACHV) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $2200.00 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-11
- Achieve Life Sciences, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $25938.00, a 1.68% decline year-over-year.
- Achieve Life Sciences, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $26381.79.
- Achieve Life Sciences, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2017-03-31 was $21.05.
- Achieve Life Sciences, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2013-03-31 was $4.11.
- Achieve Life Sciences, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2025 was $11.64, a 99.93% decline from fiscal 2024.
- Achieve Life Sciences, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $17565.33, a 31.27% decline from fiscal 2023.
- Achieve Life Sciences, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $25555.20, a 10.40% decline from fiscal 2022.
- Achieve Life Sciences, Inc. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2022 was $28522.56, a 27.25% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2200.00 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $11.64 10-K · filed 2026-03-24 | |||
| 2025-09-30 | $11.64 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $11.64 10-Q · filed 2025-08-07 | |||
| 2024-12-31 | $17565.33 10-K · filed 2025-03-11 | |||
| 2024-09-30 | $17565.33 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $24184.44 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $25938.00 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $25555.20 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $26045.33 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $26045.33 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | $26381.79 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $28522.56 10-K · filed 2023-03-16 | |||
| 2022-09-30 | $28522.56 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $28522.56 10-Q · filed 2022-08-11 | |||
| 2021-12-31 | $39204.00 10-K · filed 2022-03-10 | |||
| 2021-09-30 | $39204.00 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $39204.00 10-Q · filed 2021-08-12 | |||
| 2020-12-31 | $34874.40 10-K · filed 2021-03-11 | |||
| 2020-09-30 | $31240.00 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | $31240.00 10-Q · filed 2020-08-06 | |||
| 2017-12-31 | $114.53 10-K · filed 2018-03-01 | |||
| 2017-09-30 | $114.53 10-Q · filed 2017-11-09 | |||
| 2017-06-30 | $8.80 10-Q · filed 2017-07-31 | |||
| 2017-03-31 | $21.05 10-Q · filed 2017-05-15 | |||
| 2016-12-31 | $1.00 10-K · filed 2017-02-23 | |||
| 2016-09-30 | $7.25 10-Q · filed 2016-11-10 | |||
| 2016-06-30 | $7.25 10-Q · filed 2016-08-04 | |||
| 2015-12-31 | $2.96 10-K · filed 2017-02-23 | |||
| 2014-12-31 | $18.93 10-K · filed 2017-02-23 | |||
| 2014-09-30 | $18.93 10-Q · filed 2014-10-30 | |||
| 2014-06-30 | $18.93 10-Q · filed 2014-08-07 | |||
| 2013-12-31 | $4.11 10-K · filed 2016-03-09 | |||
| 2013-09-30 | $4.11 10-Q · filed 2013-11-07 | |||
| 2013-06-30 | $4.11 10-Q · filed 2013-08-08 | |||
| 2013-03-31 | $4.11 10-Q · filed 2013-05-02 | |||
| 2012-12-31 | $9.10 10-K · filed 2015-03-26 | |||
| 2012-09-30 | $9.10 10-Q · filed 2012-11-08 | |||
| 2012-06-30 | $3.89 10-Q · filed 2012-08-02 | |||
| 2011-12-31 | $13.95 10-K · filed 2014-03-11 | |||
| 2010-12-31 | $104.91 10-K · filed 2013-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |